AAMU
ESPR icon

Amundi Asset Management US’s Esperion Therapeutics ESPR Stock Holding History

Amundi Asset Management US’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-379,326
Closed -$9.86M – 1545
2020
Q4 		$9.86M Buy
379,326
+29,923
+9% +$896K 0.01% 812
2020
Q3 		$13M Sell
349,403
-10,061
-3% -$398K 0.01% 663
2020
Q2 		$18.4M Buy
359,464
+41,112
+13% +$1.72M 0.02% 529
2020
Q1 		$10M Sell
318,352
-8,446
-3% -$446K 0.02% 561
2019
Q4 		$19.5M Buy
326,798
+51,645
+19% +$2.32M 0.02% 574
2019
Q3 		$10.1M Buy
275,153
+3,056
+1% +$121K 0.02% 697
2019
Q2 		$12.7M Sell
272,097
-1,580
-0.6% -$74.2K 0.01% 723
2019
Q1 		$11M Sell
273,677
-384
-0.1% -$17.2K 0.02% 691
2018
Q4 		$12.6M Sell
274,061
-69,233
-20% -$3.34M 0.01% 587
2018
Q3 		$15.2M Buy
343,294
+22,479
+7% +$1.03M 0.02% 627
2018
Q2 		$12.6M Buy
320,815
+26,085
+9% +$1.32M 0.02% 661
2018
Q1 		$21.3M Buy
294,730
+56,346
+24% +$4.14M 0.03% 462
2017
Q4 		$15.7M Buy
238,384
+48,485
+26% +$2.61M 0.02% 540
2017
Q3 		$9.52M Buy
+189,899
New +$9.16M 0.03% 308

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Amundi Asset Management US's ESPR Position: Q1 2021 in Review

Amundi Asset Management US sold out of Esperion Therapeutics (ESPR) in Q1 2021, closing a stake of 379,326 shares — an estimated $9.86M sold.

Amundi Asset Management US first reported a position in ESPR in Q3 2017 and held it in 14 quarters. The position peaked at $21.3M in Q1 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q1 2021.

  • Amundi Asset Management US reported no remaining Esperion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Amundi Asset Management US sold 379,326 Esperion Therapeutics shares in Q1 2021, an estimated $9.86M.
  • Amundi Asset Management US first reported a position in Esperion Therapeutics in Q3 2017 and held it in 14 quarters.
  • Amundi Asset Management US's Esperion Therapeutics position peaked at $21.3M in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.